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Gene	electrotransfer	 (GET)	holds	great	promise	 for	 the	delivery	of	 therapeutic	agents.	
The	 skin	 serves	 as	 an	 attractive	 target	 for	 GET	 due	 to	 its	 availability	 and	 unique	 cellular	
composition.	Protein	 replacement	 therapy	and	DNA	vaccination	are	potential	applications	 for	
intradermal	GET.	The	combination	of	moderate	tissue	preheating	and	GET	has	been	shown	to	




achieve	 the	 same	expression	 levels	 as	GET	at	 ambient	 temperature,	with	a	23%	 reduction	of	
applied	voltage	or	a	50%	reduction	of	pulse	number.			
Furthermore,	moderate	tissue	pre-heating	allowed	for	delivery	to	the	deep	dermis	and	
muscle,	 suggesting	 the	 potential	 to	 reach	 systemic	 circulation,	 a	 necessary	 feature	 for	 a	
successful	protein	replacement	therapy.	This	approach	was	repeated	using	a	plasmid	encoding	
Human	Factor	 IX,	 the	blood	clotting	 factor	defective	or	absent	 in	patients	with	Hemophilia	B.	








antigen	 (pHBsAg)	 via	 a	 prime	 and	 prime	 plus	 boost	 vaccination	 protocol.	 At	 18	 weeks	 post	
vaccination,	we	observed	 that	a	high-voltage	 low-pulse	GET	condition	with	moderate	heating	
(45V	 36p	 +heat)	 generated	 antibodies	 against	 Hepatitis	 B	 surface	 antigen	 (HBsAb)	 at	 peak	
measuring	230-fold	over	an	injection	only	control.	Antibody	titers	remained	robust	over	the	30-
week	observation	period.	These	data	taken	together	suggest	that	moderate	heat-assisted	GET	
has	 the	 potential	 to	 achieve	 systemic	 delivery	 with	 an	 intradermal	 approach,	 an	 attractive	
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Electrotransfer	 involves	 applying	 an	 electric	 field	 to	 a	 cell	 or	 tissue	 to	 potentiate	 the	
delivery	of	otherwise	impermeable	aqueous	substances.	When	the	electric	field	is	applied,	the	
cell	 membrane	 becomes	 temporarily	 permeable	 to	 a	 greater	 extent	 than	when	 in	 its	 native	
state,	a	process	known	as	electroporation	(1).	Extracellular	delivery	is	possible	during	this	quick	
and	 transient	 period.	 The	 temporary	 pores	 or	 imperfections	 in	 the	 cell	 membrane,	 which	
enhance	 its	 permeability,	 are	 resolved	 once	 the	 electric	 field	 is	 removed,	 allowing	 normal	
cellular	function	to	ensue.	This	approach	is	referred	to	as	reversible	electroporation,	where	cell	
viability	 is	 maintained.	 Conversely,	 in	 the	 case	 of	 irreversible	 electroporation,	 the	 intent	 is	
cellular	destruction,	which	has	shown	efficacy	in	cancer	therapies	and	tissue	ablation	(2-5).		
In	 the	 method	 of	 gene	 electrotransfer	 (GET),	 a	 plasmid	 encoding	 a	 gene	 of	 interest	 is	
introduced	shortly	before	application	of	the	electric	field	through	pulse	stimulation.	The	applied	
pulses	cause	a	direct	electrophoretic	effect	on	 the	 injected	plasmid	DNA,	which	promotes	 its	











transported	 through	 the	 cytoplasm.	 Endosomal	 escape	 is	 the	 next	 hurdle	 for	 the	 DNA,	 after	
which	 it	must	 cross	 the	 nuclear	 envelope	 to	 be	 transcribed	 and	 translated.	 The	 transgene	 is	
finally	expressed	and	the	newly	formed	proteins	are	released	into	the	cytoplasm	(1,6).	Though	
this	appears	to	be	a	treacherous	path	for	the	plasmid,	current	work	indicates	that	cytosolic	DNA	
sensors,	 such	 as	 DNA-dependent	 activator	 of	 interferon	 regulatory	 factors/Z-DNA	 binding	
protein	1,	may	play	an	innate	role	for	DNA	trafficking	following	transfection	(7).		
Nevertheless,	 early	 studies	 demonstrated	 successful	GET	 in	 the	 rat	 liver	 and	 on	 brain	
tumors,	 indicating	enhanced	gene	delivery	efficiency	and	stability	compared	to	those	subjects	
receiving	injection	of	DNA	alone	(8,9).	Since	those	experiments,	GET	has	been	demonstrated	in	
a	 myriad	 of	 tissue	 types	 including	 smooth	 muscle,	 skin,	 skeletal	 muscle,	 and	 even	 bone.	




various	 cancers	 and	 14	 involve	 the	 testing	 and	 delivery	 of	 DNA-based	 vaccines	 with	
electroporation.	(clinicaltrials.gov;	Keyword:	electroporation,	search	date:	March	1,	2021).	
Therapeutic	utility	of	heat	
Heat	 has	 been	 used	 therapeutically	 since	 antiquity	 when	 Hippocrates	 recorded	 the	
advantages	of	fever	in	patients	suffering	from	epilepsy	(18).	Moreover,	in	1927,	the	Nobel	Prize	






the	 hallmark	 immune	 responses	 to	 infection,	 which	 has	 been	 evolutionarily	 conserved	 over	
millions	of	years	providing	a	survival	benefit	despite	its	associated	metabolic	or	damaging	risks.	
Systemic	 temperature	elevation	allows	 for	 the	activation	of	effector	molecules	and	 facilitates	
their	trafficking	throughout	the	body	(20).	
In	 the	 context	 of	 topical	 therapeutic	 heat,	 there	 are	 two	 general	 categories:	 deep	 or	
superficial	(21,22).	Deep	heat,	achieved	with	ultrasound	or	microwaves,	reaches	a	penetration	
depth	 of	 3-5	 cm.	 This	modality	 is	 preferred	 for	 treatment	 of	 deep-seated	 conditions	 such	 as	
Bursitis	or	Osteoarthritis	in	the	joints	(18,22-24).	By	contrast,	superficial	heat,	such	as	delivered	
by	 electric	 heating	 pads,	 sodium	 acetate	 packs,	 or	 patches	 for	 minor	 injuries	 or	 sprains,	 is	
applied	to	achieve	a	penetration	depth	of	less	than	1	cm	(24,25).	The	results	of	both	therapies	
are	increased	blood	flow,	elasticity	of	connective	tissue,	and	ultimately	pain	relief.	Though	the	
use	 of	 therapeutic	 heat	 is	 quite	 commonplace,	 it	 is	 critical	 that	 both	 the	 temperature	 and	
duration	 of	 exposure	 be	 monitored	 to	 receive	 the	 beneficial	 effects	 without	 the	 damaging	
effects	(21,25).		
There	are	 a	number	of	 associated	effects	of	 thermal	 application	 to	 consider	 including	
sensation,	skin	discoloration,	cellular	processes,	and	even	injury	(26-29).	Based	on	these	data,	
negative	effects	from	thermal	injury	begin	to	occur	above	44°C	(Table	1).	Thermal	injury	is	both	










Sensation	 Skin	color	 Tissue	temp		(°C)	 Cellular	process	 Tissue/cell	injury	














Hot	 Flushed	 44	 Normal		 None	





organ	of	 the	body,	 its	 sheer	 size	and	availability	make	 it	an	excellent	 target	 for	GET.	 It	 is	 the	
most	visible	and	therefore	exposed	organ.	The	skin	serves	as	the	effective	barrier	between	the	
host	and	the	outside	world.	Therefore,	it	functions	as	the	first	line	of	defense	against	infection	
and	 traumas.	Skin	acts	as	an	 insulator,	 responsible	 for	 regulating	 fluid	 loss	and	absorption	as	
well	as	temperature.		
The	anatomical	structure	of	human	skin	is	made	up	of	three	layers	from	top	to	bottom:	
the	 epidermis,	 the	 dermis,	 and	 the	 hypodermis.	 The	 arrangement	 and	 thickness	 of	 the	





epidermis	 can	 be	 found	 in	 thick	 skin	 located	 on	 the	 palms	 and	 the	 foot	 sole	 measuring	
approximately	 2	 mm	 (30,31).	 By	 contrast,	 skin	 found	 on	 the	 arm	 for	 example	 has	 an	
approximate	 epidermal	 thickness	 of	 0.8-1	 mm.	 The	 epidermis	 is	 made	 primarily	 of	
keratinocytes,	 but	 also	 includes	 melanocytes,	 Merkel	 cells,	 and	 antigen-presenting	 dendritic	






nutrition	 for	 the	 epidermis	 through	 communication	 at	 the	 epidermal-dermal	 junction.	 The	
dermis	 includes	 cells	 such	 as	 fibroblasts,	 monocytes,	 Langerhans	 cells,	 lymphocytes,	 and	
eosinophils,	but	is	mainly	comprised	of	connective	tissue	(31).	Blood	and	lymph	vessels	can	be	
found	 in	 the	 connective	 tissue	 matrix	 of	 the	 dermis.	 These	 vessels	 offer	 support	 to	 the	
epidermis	above	and	to	the	hypodermis	or	subcutaneous	tissue	below.		
The	 skin	 is	 a	 feasible	 target	 for	 GET.	 It	 is	 accessible,	 easily	monitored,	 and	 its	 highly	
immunogenic	 properties	 enhance	 its	 utility	 for	 the	 delivery	 of	 therapeutic	 agents.	 Preclinical	
studies	 have	 used	mice,	 rats,	 guinea	 pigs,	 pigs,	 and	 non-human	 primates	 as	models	 for	 skin	
research	 (32-34).	 The	 guinea	 pig	 serves	 as	 a	 good	 model	 for	 human	 skin	 because	 it	 has	
anatomical	 similarities.	 Cellular	 composition	 in	 the	 dermis	 including	 Langerhans	 cells,	 dermal	








are	 used	 to	 pierce	 the	 stratum	 corneum	 for	 pulse	 delivery.	 The	 applied	 voltage	 from	 these	
penetrating	 electrodes	 is	 dependent	 on	 design,	 but	 ranges	 anywhere	 from	 50-1750V/cm.	
Penetrating	electrodes	have	been	evaluated	as	a	platform	for	DNA	vaccination	demonstrating	
adaptive	immunity	compared	to	direct	injection	of	plasmid	DNA	(35).		
Non-Penetrating	 electrodes	 provide	 a	 non-invasive	 alternative,	 where	 the	 electrode	
does	 not	 have	 to	 be	 inserted	 in	 the	 skin	 for	 pulse	 application.	 Caliper	 and	 tweezer-type	
electrodes	were	the	early	configurations	of	non-penetrating	electrodes,	which	applied	pulses	in	
a	single	direction.	By	contrast,	four	plates	oriented	in	a	square	pattern	could	deliver	pulses	 in	
multiple	 directions	 (36).	 Though	 effective	 for	 gene	 electrotransfer,	 the	 large	 gap	 between	
electrodes	 required	 high-voltage	 or	 high-pulse	 number	 to	 achieve	 elevated	 levels	 of	 gene	




short	 gap	 between	 electrodes,	 thus	 effectively	 reducing	 the	 required	 voltage.	 This	 created	 a	
non-penetrating	minimally	invasive	approach	to	cutaneous	gene	delivery.	The	MEA	has	shown	













response.	However,	because	the	virus	has	been	attenuated	 it	 inherently	 is	 less	 immunogenic.	
Therefore,	 inducing	 a	 more	 prolonged	 immunity	 and	 requiring	 less	 frequent	 booster	
immunizations	 would	 be	 advantageous.	 Also,	 the	 aim	 to	 include	 protection	 from	 several	
pathogens	 within	 one	 vaccine	 is	 appealing,	 but	 is	 difficult	 to	 obtain	 with	 a	 live-attenuated	
platform.	 Safety	 concerns	 such	 as	 reversion	 to	 a	 live	 state	 or	 allergies,	 which	 exclude	 some	
population	cohorts,	 remain	with	current	vaccine	types.	These	 limitations	and	others	motivate	
the	development	of	alternative	vaccine	platforms.	
DNA	 vaccines	 provide	 an	 attractive	 alternative.	 They	 are	 non-live	 and	 non-replicating	
and	specifically	encode	the	antigen	or	antigens	of	interest.	In	the	early	1990s,	DNA	vaccinations	
were	 reported	 to	 induce	 antibody	 responses	 to	 viral	 or	 bacterial	 antigens	when	delivered	 to	
skin	 or	 muscle	 (41-43).	 In	 principle,	 DNA	 vaccines	 were	 able	 to	 generate	 robust	 immune	
responses	 without	 the	 need	 of	 a	 replicating	 pathogen	 to	 purify	 them.	 Success	 in	 preclinical	
studies	 helped	 facilitate	 the	 translation	 of	 DNA	 vaccines	 to	 clinical	 trials.	 The	 first	 trials	
evaluated	 the	 efficacy	 of	 a	 DNA	 vaccine	 against	 HIV-1	 (44).	 Criticism	 of	 DNA	 vaccines	
questioned	the	risk	of	genome	integration.	There	is	little	evidence	of	integration	observed	from	
DNA	 vaccines,	 and	 even	 appears	 to	 be	 lower	 in	 risk	 than	 that	 of	 naturally	 occurring	 genetic	





trials	 and	 preclinical	 studies	 have	 included	 influenza,	 Human	 Papilomavirus,	 Hepatitis	 B,	
Malaria,	 Zika	 virus,	 SARS-CoV,	 Ebola,	 and	 West	 Nile	 Virus	 (47-52).	 There	 is	 even	 a	 current	
ongoing	 clinical	 trial	 evaluating	 the	 use	 of	 a	 DNA	 vaccine	 against	 SARS-CoV-2,	 the	 causative	
agent	 of	 the	 COVID-19	 pandemic.	 Though	 safe	 and	 well	 tolerated,	 results	 of	 the	 completed	
studies	suggested	that	injection	of	plasmid	DNA	alone	was	not	very	immunogenic	(47-52).		





been	 tested	 using	 a	 GET-delivered	 DNA	 vaccine	 (49,55-62).	 Taken	 together,	 these	 results	
demonstrate	 the	 potential	 of	 GET	 to	 enhance	 the	 delivery	 DNA	 vaccines	 as	 well	 as	 their	
immunogenicity	compared	to	direct	injection.		
Primarily,	 the	 use	 of	 invasive	 penetrating	 electrodes	 has	 been	 employed	 for	 GET-
mediated	delivery	 of	DNA	 vaccines.	Muscle	 is	 the	 primary	 site	 for	 these	 applications,	 as	 it	 is	



























Conversely,	 utilizing	 gene	 therapy	 for	 this	 indication	 can	 induce	 sustained	 protein	
expression	levels,	increasing	the	time	between	repeat	administrations	(71).		Viral	vectors,	such	
as	 recombinant	 adeno-associated	 virus	 (rAAV),	 have	 shown	 some	 efficacy	 for	 the	 delivery	 of	
Factor	VIII	and	IX	proteins	(70).	Though	able	to	induce	high	levels	of	transgene	expression,	the	
use	 of	 viral	 vectors	 may	 not	 be	 suitable	 for	 all	 patients.	 A	 humoral	 immune	 response	 via	






those	 patients	 and	 eliminates	 them	 as	 potential	 therapy	 recipients.	 Also,	 a	 cell-mediated	
immune	 response	has	been	 shown	 in	 response	 to	 the	AAV	capsid,	 evidenced	by	AAV	capsid-
specific	CD8+Tcells	(73,74).	This	not	only	was	shown	to	cause	reduced	expression	potential,	but	
also	clearance	of	transduced	hepatocytes	in	liver-directed	rAAV	delivery	(68,75).	
Using	 the	 skin	 as	 an	 alternative	 delivery	 organ	 for	 protein	 replacement	 therapy	 is	
advantageous.	In	the	case	of	Hemophilia,	where	severe	bleeding	is	a	real	concern,	a	minimally	
invasive	 approach	 is	 crucial.	 A	 non-penetrating	 electrode	 is	 thus	 an	 attractive	 platform.	 Pre-
clinical	studies	in	hairless	guinea	pig	displayed	elevated	Factor	IX	protein	levels	using	the	MEA	





an	 increase	 in	 temperature	 yields	 an	 increase	 in	 cell	 permeability	 (76,77).	 This	 membrane	
dilation	can	facilitate	the	transfer	of	otherwise	impermeable	deliverables,	such	as	plasmid	DNA,	
hormone,	 or	 chemotherapeutic	 drugs	 to	 cells	 or	 tissues	 (37,78,79).	When	 the	 application	 of	
moderate	 heating	 and	 electric	 field	 is	 combined,	 these	 effects	 are	 more	 pronounced	 and	


























infrared	 laser	was	chosen	as	the	heating	source	 in	this	case	due	to	 its	speed	and	precision	at	
which	the	target	temperature	could	be	reached.		
In	our	previous	work,	a	four	pin	MEA	was	utilized	with	a	centrally	located	infrared	laser	
shining	 out	 of	 a	 single	 optical	 fiber	 for	 moderate	 heating.	 This	 worked	 well	 as	 a	 proof	 of	
principle,	 but	 the	 gap	 between	 the	 electrodes	 and	 laser	 beam	 path,	 suggested	 moderate	
heating	coverage	of	the	target	tissue	could	be	improved	(78).	In	addition,	an	applied	voltage	of	
50V	was	required	for	thermally-assisted	GET.	By	utilizing	a	16-pin	MEA	we	are	able	to	reduce	
the	electrode	 gap	due	 to	 its	 geometry	 and	 thereby	 reduce	 the	necessary	 applied	 voltage	 for	







more	 uniform	 heating	 compared	 to	 our	 previous	 design	 and	 allow	 for	 reductions	 in	 either	
necessary	 applied	 voltage	 and/or	 pulse	 number.	 We	 tested	 this	 device	 for	 the	 delivery	 of	
reporter	 genes	 to	 assess	 both	 the	 kinetics	 and	 distribution	 of	 gene	 expression	 following	





incorporated	 into	 the	 16-pin	 MEA	 would	 yield	 higher	 expression	 levels	 compared	 to	 its	
unheated	counterpart	and	that	moderate	heating	would	facilitate	applied	voltage	reduction.		
A	minimally	invasive	platform	is	advantageous	for	non-life-threatening	applications	such	





ambient	 platform	with	 our	moderately	 heated	 platform.	High-voltage	 low-pulse	 number	 and	




























or	 four	 pulses.	 In	 the	 current	 work,	 these	 pulse	 trains	 were	 administered	 as	 four	 pulses	 18	







Though	 the	 moderate	 heating	 and	 GET	 delivery	 was	 incased	 in	 a	 single	 handheld	 device,	
moderate	heating	was	always	applied	before	GET	 in	 these	experiments,	as	a	way	to	pre-heat	






laser	 (Lasermate	 Group	 Inc,	 Walnut,	 California),	 an	 optical	 fiber	 that	 delivers	 the	 infrared	
radiation	laser	light	to	the	skin,	and	an	emission	splitter.	The	infrared	laser	emitter	consisted	of	
an	optical	fiber	whose	beam	was	split	equally	among	nine	individual	optical	fibers	that	utilized	
four	 separate	 splitter	 boxes	 (Figure	 2).	 The	primary	 optical	 fiber	was	 connected	directly	 to	 a	
















for	moderate	 heating	 connects	 to	 a	 primary	 three-way	 splitter	 box.	 Three	 secondary	 splitter	
boxes	are	 then	connected	each	by	via	 three	separate	optical	 fibers	 to	 the	primary	 three-way	






















were	 then	 embedded	 in	 Optimal	 Cutting	 Temperature	 compound	 and	 frozen	 at	 −80	 °C.	 To	







All	 laser	 heating	 calibrations	 were	 performed	 by	 placing	 the	 electrode	 casing	 with	







Temperature	 distribution	 at	 sequential	 depths	 of	 200µm,	 400µm,	 and	 600µm	 were	
recorded.	 Temperature	measurements	were	 taken	 at	 a	 rate	 of	 5	 reads	 per	 second,	with	 the	




the	 next	 deepest	 layer	 and	 the	 laser	 was	 turned	 off	 at	 the	 same	 time	 that	 the	 first	 depth	


























serially	 at	 200μm	 depths	 on	 an	 upright	 cryostat.	 Serial	 pig	 skin	 sections	 were	 stacked	 with	
outermost	epidermal	face	on	top.	A	thermocouple	was	placed	at	subsequent	200μm	depths	in-
between	 each	 graft	 to	 obtain	 temporal	 temperature	 measurements	 following	 laser	 heat	
application:	 200μm,	 400μm,	 and	 600μm.	 All	 experiments	 were	 performed	 with	 the	 laser	
attached	 to	 a	micromanipulator	 to	 prevent	 excess	movement	 and	 ensure	 alignment	 for	 the	
duration	of	 the	 recorded	 time.	Temperature	measurements	were	 taken	at	5-second	 intervals	
for	a	total	of	35	seconds.	A	target	temperature	of	43°C	was	reached	before	turning	off	the	laser,	








Recellularization	 of	 human	 dermal	 constructs	 was	 performed	 using	 an	 established	
protocol	 (82).	Briefly,	DermACELL®	 (LifeNet	Health,	Virginia	Beach,	VA)	grafts	were	washed	 in	
DPBS	and	cut	into	12mm	disks	using	a	biopsy	punch,	then	washed	twice	with	complete	DMEM	
media.	 Human	 primary	 dermal	 fibroblasts	 (ATCC,	Manassas,	 VA)	 were	maintained	 in	 culture	
with	DMEM,	10%	fetal	bovine	serum,	1%	Penicillin/Streptomycin	at	37°C	and	5%	CO2.	Culture	
medium	was	 replaced	every	2-3	days.	HaCaT	cells	were	maintained	 in	 culture	using	both	 the	
same	media	formulations	and	growth	conditions	as	the	fibroblasts.	
Fibroblasts	 were	 seeded	 at	 a	 density	 of	 1x106	 cells/disk	 on	 the	 reticular	 face	 of	 the	
dermis.	After	fibroblast	attachment,	the	constructs	were	transferred	to	fresh	wells.	Fibroblasts	
were	 maintained	 on	 the	 dermis	 for	 one	 week,	 allowing	 for	 cell	 infiltration	 throughout	 the	
matrix.	On	the	papillary	face,	HaCaT	cells	were	seeded	at	a	density	of	1.5x105	cells/disk.	HaCaT	
cells	 attached	 overnight,	 and	 the	 grafts	 were	 moved	 to	 the	 upper	 chamber	 of	 Transwell	
Permeable	 Supports	 (Corning	 Incorporated,	 Life	 Sciences,	 Tewksbury,	MA).	 The	 bottom	well	
was	filled	with	fresh	media,	while	the	top	well	was	left	void	of	any	media,	effectively	lifting	the	
grafts	 to	 an	air-liquid	 interface	 (Figure	6).	 This	 action	allowed	 for	 epithelial	 cell	 stratification.	


















old	 in	 culture	when	 used	 for	 this	 experiment.	 The	 grafts	 were	 carefully	 removed	 from	 their	





dabbed	dry	using	 sterile	gauze	 to	 remove	excess	 fluid	 from	both	sides	of	 the	graft.	The	graft	
was	injected	intradermally	with	50µL	of	0.9%	physiological	saline	in	the	center	of	the	graft.	The	
graft	 was	 then	 placed,	 with	 the	 reticular	 side	 facing	 up,	 directly	 on	 top	 of	 the	 RTD	
thermocouple,	which	had	been	pre-aligned	with	the	laser	fiber	at	a	distance	of	1.5cm	from	the	
graft.	Temperature	measurements	were	also	taken	every	5	seconds.	Baseline	temperature	was	





until	 sectioned.	Grafts	were	 then	sectioned	on	a	 cryostat	 to	determine	 the	 thickness	of	each	









Figure	 7.	 H&E	 staining	 of	 recellularized	 dermal	 grafts.	 An	 H&E	 staining	 was	 performed	 on	
recellularized	 dermal	 grafts	 following	 infrared	 laser	 heating.	 Samples	 were	 fixed	 in	 4%	 PFA,	
placed	 in	OCT,	 and	 frozen	 until	 sectioning.	 Grafts	were	 sectioned	 on	 an	 upright	 cryostat.	 All	




Using	the	measuring	tool	 in	 IMAGEJ,	a	scale	was	set	 for	each	 image	using	the	existing	








Table	 2.	 Recellularized	 dermal	 graft	 thickness.	 Recellularized	 dermal	 constructs	 cultured	 for	
three	weeks	were	fixed	and	stained	using	an	H&E	protocol.	Micrographs	were	taken	on	a	Leica	
systems	 inverted	microscope	 and	 imported	 into	 IMAGE	 J	 for	measurements.	 Three	 separate	
regions	 on	 the	 graft	 were	 identified,	 measured,	 and	 averaged	 to	 determine	 graft	 thickness	
(μm).	The	standard	deviation	(stdev)	between	the	three	measurements	were	recorded.	
	 Recellularized	dermis	thickness	(μm)	 	 	
Sample	ID	 Measure	1	 Measure	2	 Measure	3	 Average	 Stdev	
1	 416.56	 417.83	 447.13	 427.17	 17.29	
2	 355.85	 363.64	 388.31	 369.27	 16.95	
3	 348.43	 357.23	 373.59	 359.75	 12.77	
4	 570.97	 706.45	 619.36	 632.26	 68.66	
5	 575.96	 699.43	 560.14	 611.84	 76.26	
6	 525.79	 518.25	 505.66	 516.57	 10.17	
	
	
Baseline	 temperature	 of	 the	 recellularized	 dermal	 skin	 grafts	 was	 recorded	 as	 18.3	 ±	
0.1°C,	with	the	skin	graft	placed	on	top	of	the	RTD	thermocouple	(Figure	8).	It	took	20	seconds	
























The	 in	 vivo	 animal	 model	 used	 for	 this	 study	 was	 the	 guinea	 pig,	 as	 guinea	 pig	 skin	
shares	similarities	 in	 thickness	and	composition	with	human	skin.	Animals	used	 for	 this	 study	
were	8-10-week-old	Female	Hartley	guinea	pigs	weighing	approximately	300-350g	at	the	time	
of	 treatment.	 The	 animals	 were	 housed	 at	 the	 Old	 Dominion	 University	 animal	 facility	 and	
procedures	 approved	 by	 the	 Old	 Dominion	 Institutional	 Animal	 Care	 and	 Use	 Committee	




placing	 the	 animals	 into	 an	 induction	 chamber	 infused	 with	 3-4%	 isofluorane	 and	 96-97%	
oxygen	 gas.	 After	 animals	 were	 sufficiently	 anesthetized,	 they	 were	 fitted	 with	 a	 standard	
rodent	 mask	 supplied	 with	 3%	 isofluorane	 and	 oxygen	 to	 maintain	 a	 surgical	 plane	 of	
anesthesia	for	the	duration	of	the	procedure.	Animals	were	placed	on	a	heating	pad	to	ensure	
thermoregulation	 during	 the	 entire	 procedure.	 Animals	 were	 then	 shaven	 and	 washed	 with	




novel	 configuration	 was	 determined.	 Temperature	 measurements	 were	 accomplished	 by	









heating	 pad	 was	 determined	 to	 be	 35°C.	 For	 moderate	 heat	 application,	 the	 electrode	 was	
placed	 with	 the	 spring-loaded	 GET	 electrode	 pins	 in	 contact	 perpendicularly	 with	 the	 skin,	
leaving	a	fixed	distance	of	1	cm	between	the	optical	fibers	and	the	skin	target.	Gentle	pressure	
was	 applied	 to	 ensure	 uniform	 contact.	 With	 the	 thermocouple	 in	 place,	 temperature	
measurements	were	then	obtained	during	the	application	of	moderate	heat.	Safety	precautions	
such	as	eyewear	and	barriers	were	in	place	during	all	laser	operations.	
We	 assessed	 the	 heating	 capabilities	 of	 three,	 six,	 and	 nine	 operating	 optical	 fiber	
configurations	 to	 determine	 which	 provided	 the	 most	 uniform,	 fast,	 and	 stable	 intradermal	
heating.	 The	 target	 intradermal	 temperature	 for	 this	 experiment	 was	 43°C,	 which	 was	
previously	determined	to	be	the	ideal	moderate	heating	temperature	for	GET	both	in	vitro	and	
in	vivo	(79,37).	An	intradermal	temperature	of	43°C	was	achieved	after	operating	the	infrared	
laser	 across	 all	 nine	 optical	 fibers	 arranged	 in	 three	 rows	 for	 30	 seconds	 at	 8	 amps.	 This	
elevated	 temperature	 was	 maintained	 for	 approximately	 30	 seconds,	 thus	 allowing	 for	 the	
maximal	20-second	GET	pulse	protocol	to	be	completed	while	the	tissue	remained	moderately	
heated	(Figure	9).	These	heating	parameters	and	duration	were	in-line	with	previously	reported	
results	 from	our	 group	 utilizing	 the	 same	 infrared	 laser	 though	 here	we	 present	 an	 updated	
applicator	design	(78).	The	temperature	remained	elevated	above	41°C	for	20	seconds.	There	











Figure	 9.	 Intradermal	 skin	 temperature	 during	 moderate	 heating.	 In	 vivo	 intradermal	
temperature	measured	by	a	K-type	thermocouple.	Baseline	temperature	was	recorded	prior	to	
each	 heating	 iteration-	 3,	 6,	 or	 9	 fibers.	 Moderate	 heating	 was	 applied	 via	 infrared	 laser	



































Before	 advancing	 to	 a	 therapeutic	model,	 the	 use	 of	 reporter	 genes	 is	 important	 for	
determining	 both	 the	 kinetics	 of	 expression	 and	 the	 distribution	 within	 the	 tissue	 following	
moderate	 heat-assisted	 GET.	 Our	 previous	 work	 demonstrated	 that	 expression	 could	 be	
enhanced	 and/or	 the	 applied	 voltage	 reduced	 by	 preheating	 the	 tissue	 prior	 to	 pulse	
administration.	In	the	current	study,	we	utilized	our	16-pin	MEA	and	incorporated	nine	optical	




While	 increased	temperature	can	enhance	delivery	when	used	together	with	GET,	 it	 is	
also	important	to	moderate	the	applied	heat	so	as	not	to	cause	tissue	damage.	We	previously	
established	 that	 the	 optimal	 intradermal	 temperature	 for	 enhancing	 GET	 was	 43°C.	 It	 takes	
several	minutes	 to	 cause	 a	 burn	 at	 43°C,	 our	 pulse	 protocol	 is	 far	 under	 this	 threshold.	We	
developed	a	moderate	heating	protocol	using	an	infrared	laser	that	demonstrated	a	30	second	
preheating	 duration	 was	 sufficient	 for	 sustained	 temperature	 during	 the	 proceeding	 pulsing	
protocol.	 Tissue	 integrity	 following	 moderate	 heat-assisted	 GET	 was	 evaluated	 through	
histological	 analysis	using	an	H&E	 staining	protocol.	 Furthermore,	 a	dosing	 study	was	 carried	
out	 where	 both	 volume	 and	 concentration	 of	 plasmid	 DNA	 were	 varied	 to	 determine	 the	





overall	 expression	 levels.	 The	 synergy	between	moderate	heating	 and	 electroporation	 allows	
for	 the	 reduction	of	both	 the	necessary	 applied	 voltage	and	pulse	number.	 These	 reductions	




Animals	 used	 for	 this	 study	were	 8-10-week-old	 Female	Hartley	 guinea	 pigs	weighing	




Animal	 euthanasia	 was	 performed	 at	 the	 conclusion	 of	 each	 respective	 observation	
period.	Euthanasia	was	carried	out	by	first	anesthetizing	the	animals	in	a	chamber	filled	with	4%	
isoflurane	 combined	 with	 96%	 oxygen.	 After	 15	minutes,	 the	 animals	 were	 transferred	 to	 a	
separate	chamber	and	euthanized	by	exposure	to	carbon	dioxide	for	15	minutes.	Compressed	
gas	was	used	as	 the	carbon	dioxide	source.	The	chamber	was	not	pre-filled,	but	slowly	 filled,	
and	 cleaned	 and	 dried	 between	 animal	 groups.	 A	 bilateral	 thoracotomy	 was	 performed	 to	
confirm	euthanasia.	This	secondary	euthanasia	procedure	was	only	performed	after	cessation	









Endotoxin-free	 plasmid	 preparations	 at	 2mg/ml	 in	 0.9%	 sterile	 injectable	 saline	 of	
gWizLuc,	encoding	firefly	luciferase,	and	gWizLuc-myc-DDK,	encoding	the	oncogene	myc	and	a	
DDK	 protein	 tag,	 were	 commercially	 prepared	 for	 this	 study	 (Aldevron,	 Fargo,	 ND).	 Both	
plasmids	have	a	gWiz	backbone	and	a	CMV	promoter.	
Infrared	laser	heat	application	
Animals	were	 anesthetized	with	O2	containing	 2.5-3.0%	 isoflurane.	 Prior	 to	 treatment	
both	 flanks	 were	 shaved	 and	 washed	 with	 mild	 soap	 and	 water	 to	 remove	 loose	 hair	 and	
cleanse	the	skin	of	any	abundance	of	oil.	Moderate	heating	via	a	Class	 IV	Laser	power	supply	
(LaserMate	 Group,	 Inc)	 via	 a	 laser	 optic	 fiber	 (Model:	M79L005	 Thor	 Labs	 Inc.)	 was	 applied	
immediately	following	a	50μL	2mg/mL	intradermal	injection	of	plasmid	DNA	to	the	pre-washed	
and	shaven	flank	skin	for	a	total	duration	of	30	seconds,	after	which	the	laser	was	switched	off.	




Animals	were	 anesthetized	with	O2	containing	 2.5-3.0%	 isoflurane.	 Animals	were	 pre-
shaven	and	washed	with	mild	soap	and	water	to	remove	any	loose	hair	or	an	overabundance	of	
oil.	 A	 100μg	 intradermal	 injection	 of	 plasmid	 DNA	was	 delivered	 to	 the	 flank.	 Injection	 sites	
were	 marked	 to	 ensure	 accuracy	 of	 data	 collection.	 The	 electrode	 array	 was	 immediately	






pulses	 respectively.	 In	 addition,	 applied	 voltages	 of	 35V	 and	 45V	 were	 assessed.	 Gene	
expression	 levels	 were	 measured	 for	 all	 conditions	 by	in	 vivo	bioluminescent	 imaging	 or	
fluorescent	imaging.		
In	vivo	bioluminescent	imaging	and	kinetic	expression	analysis	
On	 days	 2,	 5,	 7,	 9,	 and	 14,	 animals	 were	 anesthetized	 with	 O2	containing	 2.5-3.0%	
isoflurane	 followed	 by	 a	 single	 subcutaneous	 injection	 of	D-luciferin	 (Gold	 Biotechnology,	 St.	
Louis,	 MO)	 at	 150mg/kg	 administered	 at	 the	 neck	 scruff.	 The	 animals	 were	 confined	 in	 an	
anesthesia	 chamber	 for	 eight	minutes	 then	 transferred	 to	 the	 IVIS®	Spectrum	 (Perkin	 Elmer,	
Akron,	 OH),	 imaging	 chamber	 under	 constant	 anesthesia.	 Regions	 of	 interest	 (ROI)	 were	
selected	 on	 the	 image	 to	 encompass	 the	 entirety	 of	 each	 injection	 site	 independently	 and	
compared	 to	 untreated	 control	 ROIs.	 After	 background	 correction,	 bioluminescence	 results	
were	represented	as	average	total	flux	in	photons/sec	(p/s).	
Immunofluorescence	staining	and	distribution	expression	analysis	
The	 localization	 of	 gene	 delivery	 within	 the	 skin	 was	 determined	 by	
immunofluorescence	 staining	 for	 the	DDK	 tag	 protein.	 Skin	 samples	were	 collected	 48	 hours	
post	 gene	 transfer,	 fixed	 in	 4%	 paraformaldehyde,	 paraffin	 embedded,	 and	 sectioned	 to	 six-
micron	 thickness	 by	 IDEXX	 Laboratories,	 Inc.	 (Westbrook,	 Maine).	 Hematoxylin	 and	 eosin	
staining	was	also	performed	on	serial	sections	by	IDEXX	Laboratories.	Unstained	sections	were	













between	 antibody	 applications.	 Negative	 control	 samples	 were	 treated	 with	 secondary	
antibody	 only,	without	 the	 primary	 antibody.	 All	 staining	 procedures	were	 performed	 in	 the	
dark	 to	 prevent	 photobleaching.	 Samples	 were	 counterstained	 with	 DAPI	 for	 cell	 nuclei	
identification	 and	 mounted	 with	 VECTASHIELD®	HardSet™	mounting	 medium	 (Vector	




dose	 to	 achieve	 the	 highest	 expression	 level	 with	 minimum	 adverse	 tissue	 effects.	 For	 this	
experiment	 we	 used	 a	 plasmid	 encoding	 the	 reporter	 gene	 luciferase.	 Anesthesia	 was	
performed	by	placing	the	animals	 in	an	 induction	chamber	 infused	with	3-4%	isofluorane	and	
96-97%	 oxygen	 gas.	 After	 animals	 were	 sufficiently	 anesthetized,	 they	 were	 fitted	 with	 a	
standard	rodent	mask	supplied	with	3%	isofluorane	and	oxygen	to	maintain	a	surgical	plane	of	
anesthesia.	Animals	were	placed	on	a	heating	pad	to	ensure	thermoregulation	during	the	entire	






Injection	 sites	 were	 marked	 to	 ensure	 accuracy	 of	 data	 collection.	 gWizLuc	 plasmid	
doses	 included	 volumes	 of	 50	 or	 100μL	 at	 0.5,	 1,	 or	 2mg/mL.	 The	 electrode	 array	 was	
immediately	positioned	over	the	injection	area.	When	applicable,	moderate	heating	was	always	












Statistical	 significance	 between	 groups	 for	 the	 reporter	 gene	 dosing	 experiment	 was	











Moderate	 heat-assisted	 GET	 yields	 sustained	 expression	 levels	 compared	 to	 unheated	
counterpart	
Moderate	heat-assisted	GET	was	demonstrated	in	a	guinea	pig	model	using	the	reporter	
gene	 firefly	 luciferase	 as	 a	 preliminary	 tool	 to	 test	 gene	 delivery	 in	 the	 skin.	 The	 luciferase	
expression	 pattern	 following	 the	 application	 of	 various	 pulsing	 parameters	with	 and	without	
the	addition	of	moderate	heat	was	recorded	over	a	two-week	observation	period	(Figure	10A).	
Peak	 expression	 in	 vivo	 was	 observed	 48	 hours	 after	 exposure	 in	 all	 tested	 conditions.	 The	
highest	 level	of	 expression,	3.66x108	photons/second	 (p/s),	was	achieved	with	45V	36	pulses	
plus	moderate	heat	at	 this	 time	point	 (p<0.05).	Furthermore,	 this	same	condition	yielded	the	
highest	expression	levels	at	both	observation	days	5	and	7	with	a	gradual	decline	over	the	14-
day	 observation	 period	 (p<0.01).	 Results	 indicate	 that	 the	 pulse	 number	 and	 applied	 voltage	
could	be	reduced	by	50%	(72	to	36	pulses)	and	23%	(45V	to	35V)	respectively,	with	the	addition	
of	moderate	heating	via	infrared	laser	to	achieve	the	same	expression	levels.	
We	 also	 determined	 the	 effect	 of	 reducing	 the	 number	 of	 active	 optical	 fibers	 for	
applying	moderate	 heat	 to	 the	 target.	 As	 described,	 the	 infrared	 laser-heating	 component	 is	
distributed	equally	 among	nine	optical	 fibers	 that	 are	 arranged	equidistant	 in	 spans	of	 three	
across	 three	 rows.	 They	 can	 be	 blocked	 individually	 or	 by	 row,	 therefore	 allowing	 for	 sharp	
control	 of	 the	 thermal	 distribution.	We	 tested	 the	 efficacy	 of	moderate	 heat	 row	 by	 row	 in	
combination	 with	 our	 highest	 performing	 GET	 condition-	 45V	 36	 pulses.	 	 There	 was	 no	














36	 pulses	 at	 45V	 with	 (45V	 36p	 +	 heat)	 or	 without	 heating	 (45V	 36p).	 (B)	 Flexibility	 and	
distribution	of	heating	was	assessed	for	3,	6,	and	9	active	optical	fibers	followed	by	GET	at	45V	




Gene	 expression	 following	 moderate	 heat-assisted	 GET	 extended	 to	 the	 dermis	 and	
underlying	muscle	
To	determine	the	distribution	and	localization	of	gene	delivery	following	moderate	heat-
assisted	 gene	 electrotransfer,	 fluorescence	 staining	 was	 performed.	 The	 reporter	 gene,	
gWizLuc-myc-DDK,	was	delivered	 to	 guinea	pig	 skin	 via	 intradermal	 injection	with	or	without	
GET	 and	 moderate	 heat	 (Figure	 11).	 No	 expression	 was	 observed	 following	 an	 intradermal	
injection	 with	 moderate	 heat	 alone	 (Figure	 11A).	 Immunohistochemical	 evaluation	
demonstrated	 that	 expression	 was	 localized	 in	 the	 dermis	 and	muscle	 layer	 of	 the	 tissue	 in	
those	animals	receiving	moderate	heat-assisted	GET	(Figure	11F-G).	The	addition	of	moderate	
heat	 resulted	 in	 a	 higher	 level	 of	 expression	 at	 the	 reduced	 35V	 compared	 to	 the	 same	












Figure	 11.	 Distribution	 of	 expression	 following	 moderate	 heat-assisted	 GET	 to	 the	 skin.	 An	
indirect	 fluorescence	 staining	 protocol	 using	 an	 anti-DDK	 primary	 antibody	 and	 secondary	
antibody,	Alexa	 Fluor	 488,	was	 performed	on	 guinea	pig	 skin	 fixed	 in	 4%	PFA	48	hours	 after	
GET.	Samples	were	paraffin	embedded	and	sections	were	counterstained	with	DAPI.	Images	are	
representative	of	3-4	 individual	subjects.	Experimental	groups	 included	(A)	 injection	only	plus	
heat	(IO+heat),	 (B,C)	 injection	of	pDNA	followed	by	72	pulses	at	35V	at	ambient	(35V	72p)	or	



















performed	 on	 guinea	 pig	 skin	 fixed	 in	 4%	 PFA	 and	 paraffin	 embedded.	 Images	 are	
representative	of	3-4	 individual	 subjects.	 Experimental	 groups	 included	 (A)	 injection	of	pDNA	
followed	by	72	pulses	at	45V	(45V	72	p	no	heat)	and	(B)	36	pulses	at	45V	after	the	application	of	

















Peak	 luciferase	 expression	 in	 vivo	was	 observed	 48	 hours	 after	 exposure	 in	 all	 tested	
parameters	 and	 decreased	 gradually	 over	 the	 two-week	 period	 of	 observation	 (Figure	 13).	 A	
100μL	injection	at	1mg/mL	yielded	the	highest	overall	level	of	luciferase	expression	in	all	tested	
parameters	 compared	 to	 all	 other	 concentrations	 and	 volumes.	 The	 highest	 expression	 was	
shown	 in	 those	 animals	 receiving	 36	 pulses	 at	 45V	 with	 a	 total	 flux	 of	 9.9x108	 ±	 1.8x108	
photons/sec	 after	 just	 two	 days	 (Figure	 13C).	 These	 results	 were	 significant	 compared	 to	
injection	of	plasmid	DNA	alone	(p<0.001)	(Figure	13A).	Similarly,	72	pulses	at	45V	delivered	at	
ambient	temperature	following	a	100μL	injection	at	1mg/mL	resulted	in	a	total	flux	of	8.84x108	
±	5.66x108	photons/sec	 (Figure	13D).	However,	 this	 condition	 served	as	a	positive	 control,	 in	
that	 although	 expression	 levels	 were	 high,	 the	 superficial	 damage	 attributed	 to	 these	 GET	
parameters	were	unfavorable	and	negated	its	potential	use	for	translation.		
In	 the	 high-pulse,	 low-voltage	moderately	 heated	GET	 condition	 (35V	 72p	 +heat),	 the	






that	 of	 the	 other	 tested	GET	 conditions,	 these	 results	were	 significant	with	 respect	 to	 those	
animals	 receiving	 injection	 of	 plasmid	 DNA	 alone	 of	 the	 same	 volume	 and	 concentration	
(p<0.01).	 Though	 not	 significant,	 on	 observation	 days	 7	 and	 9,	 animals	 receiving	 the	 higher	









Figure	 13.	 Optimization	 of	 plasmid	 DNA	 dosing	 for	moderate	 heat-assisted	 GET	 to	 the	 skin.	
Experimental	groups	included	(A)	injection	pDNA	only	(IO),	(B)	72	pulses	at	35V	with	moderate	






p).	 Plasmid	 DNA	 doses	 included	 volumes	 of	 50	 or	 100μL	 at	 0.5,	 1,	 or	 2mg/mL.	 Luciferase	





There	are	 a	number	of	 associated	effects	of	 thermal	 application	 to	 consider	 including	
pain	 sensation,	 skin	 discoloration,	 inhibition	 of	 cellular	 processes,	 and	 injury.	 In	 the	 current	
work,	we	 present	 a	 platform	 for	 reversible	 electroporation	 in	 the	 skin,	where	 cell	 viability	 is	
maintained.	We	heat	the	skin	to	a	moderate	temperature	of	43°C	for	a	total	of	30	seconds	and	
maintain	 an	 elevated	 temperature	 for	 an	 additional	 20	 seconds	 after	 the	 exogenous	 heat	
source	 is	 removed.	Our	 previous	work	 in	 an	ex	 vivo	 pig	 skin	model	 and	 in	 a	 3D	 human	 skin	
model,	suggested	that	moderate	heating	via	an	infrared	laser	provided	fast,	uniform	heating	of	
the	 target.	 At	 this	 temperature,	 the	 skin	 is	 temporarily	 warm	 and	 normal	 metabolism	 still	
proceeds.	 We	 observed	 no	 injury	 to	 the	 skin	 after	 moderate	 heat	 was	 applied	 in	 vivo.	
Conversely,	 high	 voltages	 and	 pulse	 number	 led	 to	 skin	 damage	 both	 macroscopically	 and	
microscopically.	We	observed	this	effect	by	way	of	reddened	skin	and	confirmed	through	H&E,	
in	animals	 receiving	45V	and	72	pulses	without	moderate	heat,	 suggesting	 that	although	 this	
condition	yielded	a	high	 level	of	expression,	 it	was	damaging	and	not	 ideal	 for	 translation	for	
non-life-threatening	applications.	The	combination	of	moderate	heating	and	GET	allowed	for	a	







promising	 features	 of	 moderate	 heat-assisted	 GET,	 providing	 a	 shorter,	 less	 painful	 delivery	
platform	compared	to	high	voltage-high	pulse	GET	performed	at	ambient.	The	result	is	a	faster,	
minimally	invasive	route	of	electrotransfer.	
We	 observed	 expression	 in	 the	 lower	 dermis	 and	 muscle	 following	 moderate	 heat-
assisted	GET.	These	data	are	encouraging	as	the	propensity	for	a	deliverable	to	reach	systemic	
circulation	 is	higher	 in	 these	 tissues.	 Furthermore,	our	data	demonstrate	 that	an	 intradermal	
approach	 can	 yield	 expression	 in	 the	 muscle	 using	 a	 non-penetrating	 electrode	 with	 the	
addition	of	moderate	heating.	The	enhanced	membrane	 fluidity	associated	with	 temperature	







field	 and	 exogenous	 moderate	 heating	 source,	 given	 that	 a	 100μL	 injection	 measures	
















resilient,	 able	 to	 survive	 outside	 the	 body	 for	 up	 to	 seven	 days.	 Each	 year	 there	 are	
approximately	200,000	new	HBV	cases	in	the	US	(90).	The	symptoms	of	HBV	infection	are	non-
specific	 and	 infection	 is	 generally	 confirmed	 through	 blood	 laboratory	 analysis	 once	 latent	
indications	appear.	Preventative	HBV	vaccination	has	reduced	the	disease	burden;	however,	an	
estimated	350	million	people	worldwide	are	living	with	chronic	HBV	(91).		
Vaccination	 schedule	 compliance	 is	 critical	 for	 HBV	 prevention.	 Current	 guidelines	





risk	 of	 HBV	 infection	 by	 lengthening	 the	 period	 of	 susceptibility.	 This	 can	 have	 important	
implications	 in	 countries	 where	 HBV	 infection	 is	 endemic,	 increasing	 the	 probability	 of	
transmission.	In	this	situation,	catch-up	vaccination	of	older	children	has	relatively	little	impact	
for	prophylaxis	because	infection	may	already	have	been	acquired	by	the	time	they	present	for	





facilities,	 inadequately	 funded	 vaccination	 programs,	means	 and	 distance	 of	 travel	 to	 clinics,	
storage	logistics	and	capacity	all	hinder	immunization	coverage.	The	current	recommended	HBV	
vaccine	 is	 recombinant	 protein	 consisting	 of	 the	 viral	 envelope	 protein	 Hepatitis	 B	 surface	
antigen	and	requires	strict	cold	storage	to	maintain	its	stability	(83,90-92).		
DNA	 vaccines	 are	 an	 attractive	 alternative	 to	 standard	 vaccine	 types,	 given	 their	
innocuous	 make-up	 and	 simplicity	 of	 production	 requirements,	 however	 there	 are	 several	
pitfalls.	Previous	DNA	vaccines	in	the	clinical	pipeline	have	demonstrated	poor	cellular	uptake	
and	immunogenicity	rendering	them	inconsistent	or	ineffective	for	conferring	protection.	These	
shortcomings	 can	 be	 mediated	 through	 enhanced	 delivery	 protocols	 beyond	 the	 standard	
needle-fitted	 syringe	 administration.	 Delivery	 of	 plasmid	 encoding	 viral	 antigen	 through	 GET	
has	potential	as	a	DNA	vaccination	platform	(38,40,94-97).	A	recent	preclinical	study	delivering	
a	DNA	vaccine	via	GET	showed	HBV-specific	T-cell	responses	in	humans	(97,98).	
Here	 we	 present	 moderate	 heat-assisted	 GET	 as	 a	 novel	 vaccine	 delivery	 platform	
utilizing	a	combination	of	moderate	heating	and	non-invasive	electrotransfer	via	the	MEA.	We	
have	 previously	 shown	 the	 advantages	 of	 combining	 electrotransfer	 with	 moderate	 heating	
where	 both	 pulse	 number	 and	 applied	 voltage	 could	 be	 significantly	 reduced	 resulting	 in	 a	
shorter	and	 less	painful	method	 (37,78).	 Futhermore,	using	 the	MEA	 for	 intradermal	delivery	
has	been	shown	to	be	both	effective	and	tolerable	 (39,78,80,81,99).	Minimizing	discomfort	 is	
an	 important	 consideration	 for	 translation	 to	 non-life-threatening	 applications	 such	 as	
vaccination,	 in	which	 schedule	 compliance	 is	 critical	 to	 achieve	 immunization	 coverage.	Here	












pigs	weighing	approximately	300-350g	at	 the	 time	of	 treatment.	The	animals	were	housed	at	
the	 Old	 Dominion	 University	 animal	 facility	 and	 procedures	 approved	 by	 the	 Old	 Dominion	
Institutional	 Animal	 Care	 and	 Use	 Committee	 approval	 #17-022.	 All	 animal	 subjects	 were	




for	 this	 study.	 Briefly,	 Euthanasia	 was	 carried	 out	 by	 first	 anesthetizing	 the	 animals	 in	 a	
chamber	 filled	with	4%	 isoflurane	combined	with	96%	oxygen.	After	15	minutes,	 the	animals	
were	transferred	to	a	separate	chamber	and	euthanized	by	exposure	to	carbon	dioxide	for	15	
minutes.	Compressed	gas	was	used	as	 the	 carbon	dioxide	 source.	The	 chamber	was	not	pre-
filled,	but	slowly	filled,	and	cleaned	and	dried	between	animal	groups.	A	bilateral	thoracotomy	
was	 performed	 to	 confirm	 euthanasia.	 This	 secondary	 euthanasia	 procedure	 was	 only	








For	moderate	 heat	 application,	 the	 electrode	was	 placed	with	 the	 spring-loaded	 GET	




enabling	 the	 tissue	 to	 remain	 heated	 during	 its	 application.	 Moderate	 heating	 was	 always	
applied	 prior	 to	 and	 never	 concurrently	 with	 GET.	 Safety	 precautions	 such	 as	 eyewear	 and	
barriers	were	in	place	during	all	laser	operations.	All	staff	were	trained	and	received	operation	





pins	 arranged	 in	 a	 4x4	 pattern	 at	 2-mm-apart.	 Each	 pair	 of	 electrodes	 was	 programmed	 to	
administer	either	a	train	of	four	pulses	with	total	72	pulses	or	two	pulses	for	a	total	of	36	pulses	
depending	 on	 pulsing	 conditions.	 The	 applied	 voltage	 was	 either	 35	 or	 45	 V	 between	 two	
conductive	 pins,	 each	with	 a	 pulse	 duration	 of	 150	ms	 and	 a	 150	ms	 delay	 between	 pulses.	









For	 the	 HBV	 vaccination	 study,	 endotoxin-free	 plasmid	 encoding	 Hepatitis	 B	 surface	
antigen	 (gWizHBsAg)	was	 professionally	 prepared	 and	 suspended	 to	 2	mg/mL	 in	 0.9%	 sterile	
injectable	saline	(Aldevron).	The	plasmid	has	a	gWiz	backbone	and	a	pCMV	promoter.		
Moderate	heat-assisted	GET	delivery	of	pHBsAg		
Female	 guinea	 pigs	 weighing	 approximately	 350	 g	 were	 used	 for	 this	 study	 as	 they	
represent	 a	model	 for	 human	 skin.	 Anesthesia	was	 performed	 as	 previously	 described.	 After	
animals	were	sufficiently	anesthetized,	they	were	fitted	with	a	standard	rodent	mask	supplied	
with	3%	isofluorane	and	97%	oxygen	to	maintain	a	surgical	plane	of	anesthesia.	The	right	flank	
was	 shaved	 and	 washed	 in	 the	 same	 aforementioned	 fashion,	 ensuring	 the	 removal	 of	
sebaceous	 oils	 prior	 to	GET.	Moderate	 heat-assisted	GET	was	 applied	 after	 the	 preoperative	
cleansing	procedure.	The	 five	 tested	groups	 included:	 IO	+	heat	 (injection	of	plasmid	without	
GET	and	with	moderate	heating),	pHBsAg+45V	36p	(plasmid	with	high-voltage	low-pulse	GET),	
pHBsAg+45V	 36p+heat	 (plasmid	 with	 moderate	 heating	 and	 high-voltage	 low-pulse	 GET),	















detect	 anti-HBs	 in	 all	 animal	 subjects.	 Sera	 was	 collected	 via	 a	 jugular	 vein	 puncture	 and	
isolated	 in	 serum	 separator	 tubes,	 which	 were	 then	 assayed	 per	 the	 manufacturer’s	























been	previously	 tested	 for	 gene	 expression	 in	 the	 dosing	 optimization	 experiment.	 Based	on	
results	from	the	dosing	experiment,	an	intradermal	injection	of	100μL	at	1mg/mL	was	used	for	
this	 work.	 GET	 parameters	 for	 DNA	 vaccination	 against	 HBV	 included:	 injection	 only	 plus	
moderate	 heating,	 45V	 36	 pulses	 with	 and	 without	 moderate	 heating,	 35V	 72	 pulses	 plus	
moderate	 heating,	 and	 45V	 72	 pulses	 without	moderate	 heating.	 Guinea	 pigs	 were	 injected	
with	 pHBsAg	 followed	 by	 appropriate	 GET	 and/or	 moderate	 heating	 conditions.	 A	 boost	









titers	 in	 this	 condition	 (45V	 36p	 +heat)	 peaked	 and	 were	 230-fold	 higher	 than	 those	 in	 an	
injection	 only	 control	 with	 moderate	 heating	 (IO	 +heat)	 (p<0.001).	 Furthermore,	 antibody	






Though	 the	 plasmid	 dosing	 experiment	 carried	 out	 with	 the	 luciferase	 reporter	 gene	
indicated	that	expression	levels	following	GET	with	45V	72	pulses	were	similar	to	45V	36	pulses	
plus	 moderate	 heating,	 we	 did	 not	 observe	 such	 similarities	 in	 HBsAb	 antibody	 production	
between	these	 two	treatments.	Specifically,	at	peak	antibody	production,	45V	36	pulses	with	

















determine	 baseline	 levels	 of	 circulating	 HBsAbs.	 HBsAb	 titer	 in	 serum	 was	 measured	 by	 an	
ELISA.	Two	standard	deviations	from	the	mean	of	this	baseline	served	as	a	positive	result.	Serial	
dilutions	were	performed	on	the	serum	samples	to	accommodate	these	criteria.	The	results	are	




Moderate	 heat-assisted	 GET	 elicits	 significantly	 higher	 HBsAbs	 after	 both	 prime	 and	 boost	
vaccination	schedules		
HBV	 DNA	 vaccination	was	 evaluated	 after	 a	 single	 primary	 dose	 to	 determine	 HBsAg	










all	 other	 GET	 conditions	 (Figure	 15).	 At	 week	 6,	 HBsAb	 titers	 were	 3-fold	 higher	 in	 the	
experimental	 condition	 45V	 36	 pulses	 with	 moderate	 heating	 compared	 to	 its	 ambient	
counterpart	(45V	36p)	(p<0.05).	Similarly,	this	condition	was	1.73	and	2.5-fold	higher	than	45V	
72	pulses	without	moderate	heating	and	35V	72	pulses	plus	moderate	heating	respectively.		
Overall,	 antibody	production	 from	 the	prime	protocol	was	 far	 lower	 than	 those	 levels	
achieved	from	two	doses:	a	prime	and	boost	given	two	weeks	apart.	However,	though	a	lower	
level	 of	 antibody	 production	 was	 observed,	 the	 same	 trends	 between	 the	 tested	 GET	












animals	 received	 an	 intradermal	 injection	 of	 a	 plasmid	 encoding	 Hepatitis	 B	 surface	 antigen	
(pHBsAg)	in	a	100μL	volume	at	1mg/mL.	Experimental	injection	of	pDNA	followed	by	GET	with	
72	pulses	 at	45V	 (45V	72	p),	 72	pulses	 at	35V	with	moderate	heat	 (35V	72p	+	heat),	 and	36	
pulses	 at	 45V	 with	 (45V	 36p	 +	 heat)	 or	 without	 moderate	 heating	 (45V	 36p).	 Serum	 was	
collected	 via	 jugular	 vein	 puncture	 6,	 11,	 18,	 24,	 and	 30	 weeks	 after	 immunization.	 Serum	












Whole-pathogen	 and	 subunit	 vaccines	 predominate	 current	 vaccine	 schedules	 (100).	
Whole-pathogen	 vaccines	 contain	 either	 killed	 or	 live-attenuated	 or	 weakened	 strains	 that	
cannot	 cause	 disease,	 but	 are	 able	 to	 elicit	 an	 immune	 response.	 Subunit	 vaccines	 are	
comprised	 of	 only	 the	 essential	 antigens	 of	 a	 particular	 pathogen	 along	 with	 adjuvants	 to	
achieve	long-term	immunity,	as	antigen	alone	is	often	not	enough	to	confer	protection.	Though	
effective,	 these	 formulations	 require	 strict	 cold	 storage	 to	 maintain	 stability,	 are	 costly	 to	
manufacture,	 require	multiple	 scheduled	 doses	 to	 achieve	 life-long	 protection,	 and	 can	 have	
serious	 side	effects	 in	 some	 recipients,	 such	as	 those	with	allergies	or	 compromised	 immune	
systems,	and	in	rare	cases	can	lead	to	reversion	to	a	disease-causing	state	(100-102).	
DNA	 vaccines	consist	 of	 a	 plasmid	 that	 carries	 genes	 encoding	 proteins	 from	 the	
pathogen	 of	 interest	 (95-97).	When	 delivered,	 the	 plasmid	 enters	 host	 cells	 and	 serves	 as	 a	
genetic	 template	 for	 the	 translation	 of	 its	 antigen.	 DNA	 vaccines	 are	 non-live	 and	 non-
replicating,	 leaving	little	risk	for	secondary	infection	from	vaccination.	Due	to	well-established	
production	protocols,	DNA	plasmid	vaccines	can	be	made	rapidly,	shortening	the	time	between	






to	 their	 robust	 temperature	 stability,	 specificity	 to	 target	 antigen,	 and	 ease	 of	 large-scale	
manufacturing.	 These	 advantages	 make	 DNA	 vaccines	 an	 inexpensive	 option	 and	 therefore	





methods	 of	 GET	 are	 used	 both	 in	 vitro	 and	 in	 vivo	 and	 are	 well	 tolerated	 in	 living	 tissues	
(11,15,16,37,40,80).	 By	 adding	 moderate	 heating	 to	 this	 approach,	 there	 is	 an	 increase	 in	
membrane	 fluidity	 allowing	 for	 the	widening	of	 the	 transient	permeations	 already	 caused	by	
GET	(76,106,107).	Thus,	the	interaction	of	moderate	heating	and	GET	affords	both	a	reduction	
in	 the	 necessary	 pulse	 number	 and	 applied	 voltage	 to	 achieve	 a	 similar	 or	 enhanced	 result	
(37,78).	 In	 practice,	 moderate	 heat-assisted	 GET	 provides	 a	 faster	 and	 less	 painful	 delivery	
platform	with	all	the	same	benefits	as	ambient	GET.	
In	 the	 current	 work,	 we	 evaluated	 the	 use	 of	 moderate	 heat-assisted	 GET	 for	 the	
delivery	of	a	DNA	vaccine	against	HBV.	Our	initial	testing	to	confirm	plasmid	dosing	allowed	for	
more	prudence	 in	determining	 the	proper	volume	and	concentration	of	plasmid	 to	deliver	 in	
our	vaccination	study.	We	found	that	a	100μL	injection	at	1mg/mL	achieved	the	highest	level	of	
luciferase	 expression	 when	 followed	 by	 45V	 36	 pulses	 with	 moderate	 heating.	 This	 is	 likely	
attributed	 to	 better	 coverage	 of	 the	 plasmid	 DNA	 injection	 by	 the	 applied	 electric	 field	 and	
exogenous	 moderate	 heating	 source,	 given	 that	 a	 100μL	 injection	 measures	 approximately	





determined	 that	 a	 total	 concentration	 of	 100μg	 achieved	 the	 highest	 expression	 levels	
(37,39,78,80,82).	Our	results	are	in	line	with	these	data.	
In	all	of	our	experiments	we	chose	to	use	45V	72	pulses	as	a	positive	control,	which	in	
our	 experience	 is	 a	MEA	 condition	 that	 reliably	 induces	 high	 expression	 levels.	However,	we	
hypothesized	this	high-voltage	high-pulse	condition	would	not	be	suitable	for	translation	due	to	
observable	skin	damage	caused	from	its	application.	On	this	basis,	we	sought	to	reduce	either	
the	 pulse	 number	 and/or	 the	 applied	 voltage	 with	 the	 addition	 of	 moderate	 heat	 to	
compensate	for	expression	loses	all	while	maintaining	tissue	health.	Tissue	health	is	critical	for	
reversible	electroporation	approaches	such	as	GET,	where	live	cells	are	needed	to	achieve	gene	
expression	 in	 the	 host.	 Furthermore,	 in	 non-life-threatening	 applications	 such	 as	 vaccination	
visible	 scarring	 and	 pain	 at	 the	 delivery	 site	 are	 unappealing	 side	 effects.	 These	 could	 be	
overlooked	in	some	cases,	where	the	benefit	outweighs	the	detriment	of	the	side	effect,	but	it	
is	not	 ideal.	We	 found	 that	with	 the	addition	of	moderate	heat,	we	were	able	 to	 reduce	 the	
applied	 voltage	by	23%	and	 the	pulse	number	by	50%	all	while	 achieving	 a	 similar	 luciferase	
expression	level	and	eliminating	the	tissue	damaging	side	effects.	
For	the	delivery	of	a	DNA	vaccine	against	HBV,	we	evaluated	both	a	prime	and	a	prime	
plus	 boost	 vaccination	 protocol.	 We	 found	 that	 GET	 parameters	 of	 45V	 36	 pulses	 with	 the	
addition	of	moderate	heat	 far	 exceeded	 the	 serum	 levels	 of	HBsAbs	produced	by	 any	of	 the	
other	GET	conditions	we	tested	in	both	the	prime	and	prime	plus	boost	vaccination	protocols.	
These	 levels	 were	 especially	 elevated	 in	 those	 animals	 receiving	 the	 prime	 plus	 boost	
vaccination	schedule	and	remained	stable	during	the	entire	30-week	observation	period.	This	





are	 long	 lasting.	 Vaccine	 longevity	 is	 just	 as	 critical	 as	 compliance,	 so	 these	 results	 are	
encouraging.	 Furthermore,	 all	 of	 the	GET	 conditions	we	 evaluated	 induced	 significant	HBsAb	
production	compared	to	injection	of	pHBsAg	alone.	Interestingly,	though	the	high-voltage	high-












multiple	 booster	 vaccinations,	 an	 appealing	 solution	 for	 all	 parties.	 The	 current	 vaccination	
schedule	 for	 HBV	 in	 infants	 recommends	 a	 series	 of	 3	 shots:	 shortly	 after	 birth,	 aged	 1-2	
months,	and	6-18	months	(86,92,93).	








essential	 aspect	 of	 an	 effective	 vaccine,	mediated	 by	 both	 the	 cellular	 and	 humoral	 immune	
systems	 and	 dependent	 upon	 the	 specificity	 for	 the	 plasmid-encoded	 antigen	 (103,108-111).	




observed	 after	 DNA	 vaccination	 in	 our	moderately	 heated	 GET	 condition	 (45V	 36p	 +heat)	 is	
evidence	that	muscle	delivery	with	an	intradermal	approach	is	not	only	possible,	but	also	more	
than	 likely	occurring.	 This	 is	 favorable,	 as	most	 vaccines	 require	muscle	delivery,	 though	 it	 is	
unclear	if	their	administration	is	precise	as	muscle	is	an	underlying	unseen	tissue	that	is	not	so	
easily	monitored.	 In	addition,	 intramuscular	vaccinations	 typically	administered	 in	 the	deltoid	
muscle	 can	 cause	 upper	 arm	 injury,	 bursitis,	 or	 other	 shoulder	 dysfunctions	 if	 not	 carefully	
administered	(112-115).	 In	 infants,	 intramuscular	vaccinations	are	given	 in	the	vastus	 lateralis	
located	 in	 anterolateral	 thigh.	 This	 site	 has	 been	 deemed	 the	 safest	 intramuscular	 route,	
though	the	middle	of	 the	muscle	should	be	 the	 target,	not	 the	upper	or	 lower	portion,	as	 its	
adjacency	to	the	muscle	branch	of	the	femoral	nerve	and	the	lateral	circumflex	femoral	artery	
(115-117).	 Intradermal	 delivery	 by	 contrast	 is	 visible	 and	 therefore	 easier	 to	 ensure	 correct	
administration.	With	moderate	heat-assisted	GET	there	are	the	advantages	of	muscle	delivery	
with	an	intradermal	approach.	
We	 have	 previously	 shown	 the	 utility	 the	 MEA	 device	 for	 DNA	 vaccination	 with	 a	








moderate	 heat-assisted	 GET	 yields	 a	 significantly	 higher	 and	 longer	 duration	 of	 expression	
compared	 to	 needle-fitted	 syringe	 injection	 alone	 in	 vivo.	 As	 a	 proof	 of	 principle,	 we	 show	
enduring	 antibody	 production	 against	 HBV	 in	 vivo	 over	 a	 period	 of	 30	 weeks	 following	
moderate	 heat-assisted	 GET.	 Compared	 to	 our	 original	 work,	 adding	 moderate	 heat	 to	 GET	
induced	 antibody	 production	 nearly	 8-fold	 over	 GET	 using	 the	MEA	 at	 ambient	 temperature	
(118).	 These	 results	 indicate	 the	 synergy	 between	moderate	 heat	 and	GET	 to	 enhance	 gene	





















A	 number	 of	 clinical	 trials	 have	 shown	 positive	 results	 for	 gene-based	 therapies	
(119,120).	Expression	of	the	delivered	gene	must	be	controlled	in	order	to	achieve	an	effective	
therapeutic	 outcome	 while	 minimizing	 toxicity	 and	 other	 adverse	 effects.	 Though	 effective,	
cutaneous	GET	requires	elevated	electric	fields	to	penetrate	the	stratum	corneum.	A	minimally	
invasive	method	 that	does	not	 require	 the	use	of	high	electric	 fields	would	 facilitate	delivery	
with	minimal	local	discomfort	and	could	potentially	reduce	or	eliminate	visible	scaring.	
To	 enhance	 the	 translatability	 of	 GET	 it	 is	 imperative	 to	 modify	 the	 approach	 in	 a	
manner	 that	 could	 use	 lower	 applied	 voltage	 while	 maintaining	 expression	 and	 thereby	
reducing	 potential	 tissue	 damage.	 The	 second	 issue	 is	 to	 be	 able	 to	 achieve	 delivery	 in	 a	
minimally	invasive	manner	to	the	deep-	or	sub-dermis.	One	concept	to	achieve	this	is	to	reduce	
the	distance	between	electrodes.	We	have	previously	shown	the	efficacy	a	non-invasive	MEA	
for	 gene	 electrotransfer	 to	 the	 skin	 that	 utilizes	 a	 short	 gap	 between	 electrodes	
(36,80,81,107,118).	While	this	approach	improved	the	outcome	with	respect	to	reduced	tissue	
damage,	expression	was	 still	 confined	 to	 the	epidermis	 (80).	 Therefore,	 alternative	 strategies	
were	explored	to	further	improve	tissue	effect	as	well	as	to	achieve	deeper	penetration.	GET	is	
generally	 considered	 a	 nonthermal	 process	 wherein	 a	 high	 voltage	 pulse	 is	 applied	 creating	








While	 increased	temperature	can	enhance	delivery	when	used	together	with	GET,	 it	 is	
also	 important	 to	 moderate	 the	 applied	 heat	 so	 as	 not	 to	 cause	 tissue	 damage.	 It	 is	 well	
established	 that	 thermal	 injury	 is	 determined	 by	 temperature	 and	 duration	 such	 that	 as	 the	
temperature	 is	 increased,	 the	 less	 time	 it	 takes	 to	 cause	 burning	 or	 tissue	 damage	 (29).	We	
previously	established	that	 the	optimal	 intradermal	 temperature	 for	enhancing	GET	was	43°C	
(78).	The	synergy	of	this	moderate	heating	protocol	and	GET	resulted	in	a	shorter,	lower	voltage	
treatment,	 presumably	 more	 tolerable	 than	 a	 high-voltage	 high-pulse	 number	 approach.	







moderate	 heating	 as	 an	 adjuvant	 to	 non-invasive	 GET	 may	 yield	 higher	 or	 more	 sustained	
Factor	IX	protein	expression.		
The	 current	work	 demonstrates	 the	 utility	 of	moderate	 heat-assisted	GET	 to	 the	 skin	
using	a	novel	application	device	based	on	the	design	of	the	MEA.	With	this	device,	the	addition	









For	 this	 reason,	 we	 suggested	 the	 use	 of	moderate	 heat-assisted	 GET	 for	 delivery	 of	
human	clotting	factor	IX.	Factor	IX	is	a	plasma	protein	that	is	critical	for	thrombosis.	Hemophilia	
B	is	an	X-chromosome	linked	genetic	bleeding	disorder	in	which	patients	are	variably	deficient	
in	 Factor	 IX,	with	 ranges	 below	 the	 normal	 50-100%	plasma	protein	 content	 (121).	 It	 affects	
approximately	 one	 in	 30,00	 live	 births	 and	 20%	 of	 all	 Hemophiliacs.	 Current	 therapy	 for	
Hemophilia	 B	 requires	 frequent	 dosages	 administered	 via	 injection	 or	 central	 line.	 These	
formulations	 are	 either	 recombinant	 protein	 or	 plasma-derived	 product	 and	 have	 short	 half-
lives.	Plasmid	DNA	by	 contrast	 to	 the	aforementioned	platforms	 is	 self-stable,	 inexpensive	 to	
produce,	and	innocuous.	In	the	last	five	years	there	have	been	viral	gene	therapy	clinical	trials	
using	 rAAV	 to	 deliver	 Factor	 IX	 (121-123).	 Though	 there	 has	 been	 some	 success	 in	 showing	
extended	therapeutic	benefit,	use	of	this	therapy	in	patients	such	as	children,	those	with	pre-
existing	 immunity	 to	 AAV,	 and	 those	 with	 hepatitis	 have	 been	 excluded.	 To	 mediate	 this,	
transient	immune	suppression	or	a	gain	of	function	Factor	IX	variants	have	been	suggested	to	
alleviate	the	unintended	side	effects	from	using	an	AAV	vector	(68,75,124).	For	these	reasons	
non-viral	 alternatives	 should	 be	 considered.	 Moreover,	 a	 minimally	 invasive	 route	 of	
administration	 to	 the	 skin	 rather	 than	 to	 the	 liver,	 the	 natural	 site	 of	 Factor	 IX	 production,	
would	be	ideal	in	this	clinical	situation	where	the	risk	of	severe	bleeding	is	a	real	concern.		
The	high	expression	levels	potentiate	the	use	of	moderate	heat-assisted	GET	for	protein	
















to	 human	 skin.	 Animals	 used	 for	 this	 study	 were	 8-10-week-old	 Female	 Hartley	 guinea	 pigs	
weighing	 approximately	 300-350g	 at	 time	 of	 procedures.	 Animal	 weights	 were	 monitored	
weekly.	The	animals	were	housed	at	the	Old	Dominion	University	animal	facility	and	procedures	













Animals	were	 anesthetized	with	O2	containing	 2.5-3.0%	 isoflurane.	 Prior	 to	 treatment	
both	 flanks	 were	 shaved	 and	 washed	 with	 mild	 soap	 and	 water	 to	 remove	 loose	 hair	 and	
cleanse	the	skin	of	any	abundance	of	oil.	This	washing	procedure	was	previously	described	 in	
Chapters	III	and	IV.	Moderate	heating	via	a	Class	IV	Laser	power	supply	(LaserMate	Group,	Inc)	
via	 a	 laser	 optic	 fiber	 (Model:	M79L005	 Thor	 Labs	 Inc.)	was	 applied	 immediately	 following	 a	
50μL	2mg/mL	intradermal	injection	of	plasmid	DNA	to	the	pre-washed	and	shaven	flank	skin	for	
a	 total	duration	of	30	 seconds,	 after	which	 the	 laser	was	 switched	off.	All	 safety	precautions	
were	adhered	to	while	the	laser	was	in	operation,	including	eye	protection	and	barriers.		
Electrode	design	
A	 novel	 applicator	 was	 constructed	 that	 enabled	 the	 administration	 of	 moderate	








fiber	 was	 connected	 to	 an	 infrared	 semiconductor	 laser,	 providing	 up	 to	 8W	 of	 irradiative	
power	 at	 a	wavelength	 of	 approximately	 900	 nm.	 The	 design	 of	 the	 electrode	was	modeled	








Animals	 were	 anesthetized	 with	 O2	containing	 2.5-3.0%	 isoflurane.	 As	 previously	
described	 in	 the	 other	 moderate	 heat-assisted	 GET	 studies,	 animals	 were	 pre-shaven	 and	




150ms	 pulses	 were	 delivered,	 yielding	 a	 total	 of	 36	 and	 72	 pulses	 respectively.	 In	 addition,	



















21,	 35,	 63,	 and	 100.	 All	 collections	 were	 performed	 while	 animals	 were	 anesthetized	 with	
O2	containing	2.5-3.0%	 isoflurane.	Animals	were	monitored	until	 recovery	 from	anesthesia	as	
evidenced	by	the	ability	to	maintain	sternal	recumbency.	Blood	was	allowed	to	clot	for	at	least	
one	hour	 at	 room	 temperature	 in	 serum	 separator	 tubes.	 Serum	was	 carefully	 collected	 and	
used	to	measure	clotting	factor	IX	content	via	a	Human	Factor	IX	ELISA	kit	(ab188393,	Abcam).		
Statistical	analysis	






To	 assess	 the	 efficacy	 of	 moderate	 heat-assisted	 GET	 for	 cutaneous	 delivery	 of	 a	
therapeutic	 protein,	 human	 Factor	 IX	was	 delivered	 via	 this	 platform	 in	 a	 guinea	 pig	model.	
Serum	was	collected	from	animals	following	GET.	Systemic	Factor	IX	content	was	reported	over	







The	 other	 intradermal	 conditions,	 moderately	 heated	 or	 not,	 followed	 a	 similar	 protein	
expression	pattern,	though	not	at	such	a	high	level	as	the	latter.	We	included	an	intramuscular	
GET	(IM	100V/cm)	condition	to	serve	as	a	positive	control	for	Factor	IX	delivery.	Conversely	to	
the	 intradermal	 GET	 results,	 Factor	 IX	 protein	 levels	 following	 intramuscular	 delivery	
experienced	an	 initial	 lag	and	peaked	at	8.43ng/mL	±	0.50	at	35	days	(p<0.01).	This	 increased	



















on	 the	 same	 flank	 in	 respective	 animal	 subjects.	 Serum	 was	 collected	 from	 the	 animals	
following	treatment.	Systemic	Factor	IX	protein	levels	were	recorded	over	a	period	of	100	days	




receiving	 just	 two	 application	 sites,	 while	 those	 receiving	 3	 or	 4	 sites	 maintained	 elevated	























for	protein	 replacement	 therapy.	Elevated	and	 long-lived	protein	expression	 is	 critical	 for	 the	
treatment	of	conditions	such	as	Hemophilia	B,	where	less	frequent	visits	mean	fewer	injections	
or	 infusions	 carrying	 a	 lower	 risk	 of	 severe	 bleeding.	 In	 Chapter	 III,	 we	 demonstrated	 that	
moderate	 heat-assisted	 GET	 yielded	 a	 significantly	 higher	 and	 longer	 duration	 of	 expression	
compared	 to	needle-fitted	syringe	 injection	alone,	where	both	 the	pulse	number	and	voltage	
were	reduced	by	50%	and	23%	respectively	with	the	addition	of	moderate	heating.	Expression	
distribution	 was	 localized	 in	 the	 dermis	 and	 muscle	 layers,	 which	 we	 surmise	 would	 be	
advantageous	 for	 applications	 such	 as	 Factor	 IX	 protein	 replacement	 therapy,	 for	 achieving	
sustained	protein	expression	levels.		
We	 included	 an	 intramuscular	 GET	 delivery	 dose	 in	 our	 Factor	 IX	 experiment	 as	 a	




to	 our	 intradermal	 GET	 delivery,	 peak	 expression	was	 observed	 14	 days	 following	moderate	
heat-assisted	GET	at	45V	72	pulses,	where	expression	levels	after	IM	GET	were	2.5-fold	lower	at	
this	same	time	point	(p	<0.05).		








than	 5%	 but	 less	 than	 50%	 total	 plasma	 protein	 content.	 We	 addressed	 this	 concern	 by	
evaluating	the	scalability	of	moderate	heat-assisted	GET	for	Factor	IX	delivery.	In	this	case,	we	

























GET	 for	 intradermal	 delivery	 in	 two	 applications:	 DNA	 vaccination	 and	 protein	 replacement	
therapy.	 Optimization	 of	 the	 infrared	 laser	 as	 the	 exogenous	 moderate	 heating	 source	 was	
carried	out	in	an	ex	vivo	pig	skin	model	as	well	as	a	3D	human	skin	model	before	in	vivo	studies	





therapeutic	agents	 to	assess	 ideal	parameters	 for	achieving	high	expression	 levels.	We	 found	
that	 a	 high-voltage	 low-pulse	 number	 condition	 plus	 moderate	 heating	 (45V	 36p	 +heat)	
resulted	 in	a	significant	 increase	 in	 luciferase	expression	compared	to	any	of	the	other	tested	
conditions.	 These	 results	were	 similar	 to	 a	positive	 control	 condition,	high-voltage	high-pulse	
number	 (45V	 72p),	 which	 displayed	 burning	 at	 the	 treatment	 site	 and	 therefore	 deemed	
unsuitable	 for	 translation	 to	 non-life-threatening	 applications.	 Conversely,	 despite	 displaying	
high	 expression	 levels,	 no	 skin	 damage	 was	 observed	 in	 the	 moderately	 heated	 condition.	
Expression	distribution	was	 found	to	extend	to	the	deep	dermis	and	muscle	of	 those	animals	







We	 evaluated	 the	 utility	 of	 moderate	 heat-assisted	 GET	 for	 the	 delivery	 of	 a	 DNA	
vaccine	against	HBV.	We	previously	found	that	a	plasmid	dose	of	100μL	at	1mg/mL	induced	the	
highest	 reporter	 gene	 expression,	 so	 this	 dose	was	 utilized	 for	 the	DNA	 vaccination	 study.	 A	
plasmid	 encoding	 Hepatitis	 B	 surface	 antigen	 was	 given	 in	 a	 prime-boost	 and	 prime	 only	
vaccination	protocol.	Our	data	indicate	that	neutralizing	antibodies	to	HBsAg	were	elevated	in	
serum	 230-fold	 over	 injection	 of	 plasmid	 DNA	 alone	 in	 those	 animals	 receiving	 our	 highest	
expressing	 condition	 (45V	 36p	 +heat).	 Antibody	 titers	 peaked	 18	 weeks	 after	 a	 prime-boost	
vaccination	protocol	and	remained	elevated	over	all	other	tested	conditions	for	the	duration	of	
the	 30-week	 observation	 period.	 We	 did	 not	 observe	 this	 high	 level	 of	 HBsAb	 in	 our	 high-
voltage	high-pulse	positive	control	condition	(45V	72p),	suggesting	the	damage	observed	with	
this	 condition	 was	 too	 severe	 to	 generate	 a	 robust	 antibody	 response.	 Due	 to	 the	 high	
generation	of	antibodies	following	the	prime-boost	protocol,	we	evaluated	antibody	generation	
with	 this	 platform	 using	 a	 prime	 only	 protocol.	 Vaccine	 compliance	 is	 a	 concern,	 so	 the	
advantage	of	a	single	dose	vaccination	compared	to	a	boost	protocol	is	less	vaccinations,	which	













peaked	 at	 14	 days	 near	 10ng/mL,	 ten-fold	 below	 therapeutic	 levels.	 We	 included	 an	
intramuscular	GET	delivery	 condition	as	a	positive	 control.	 Factor	 IX	expression	peaked	at	35	
days	 following	 GET	 as	 the	 intradermal	 GET	 conditions	 were	 waning.	 Taken	 together	 this	 is	
encouraging,	 suggesting	 the	utility	of	 a	 two-armed	delivery	 approach	using	both	 IM	GET	and	
moderate	 heat-assisted	 GET,	 to	 achieve	 both	 the	 early	 Factor	 IX	 expression	 with	 moderate	
heat-assisted	 GET	 and	 the	 lagged	 but	 sustained	 levels	 achieved	 with	 IM	 GET.	 While	 these	




These	 data	 suggest	 the	 platform	 is	 scalable,	 and	 therefore	 updates	 to	 the	 electrode	
configuration	could	further	enhance	the	utility	of	this	technology.	An	infrared	laser	was	chosen	
as	 the	 heating	 source	 in	 this	 case	 due	 to	 its	 speed	 and	 precision	 at	 which	 the	 target	
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